107754-55-2

Upstream product

• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 94-52-0 5-nitrobenzimidazole 
• 94-52-0 6-nitro-1H-benzo[d]imidazole 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 

Downstream Products

• 107754-54-1 methyl 4-<(6-aminobenzimidazol-1-yl)methyl>-3-methoxybenzoate 
• 107786-78-7 N-<4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoyl>benzenesulfonamide 
• 107786-77-6 N-[4-[6-(2-cyclopentylacetamido)benzimidazol-1-ylmethyl]-3-methoxybenzoyl]-benzenesulphonamide 
• 107754-53-0 methyl 4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoate 
• 107786-75-4 methyl 4-<<6-(2-cyclopentylacetamido)benzimidazol-1-yl>methyl>-3-methoxybenzoate 
• 107754-56-3 4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoic acid 
• 107786-76-5 4-<<6-(2-cyclopentylacetamido)benzimidazol-1-yl>methyl>-3-methoxybenzoic acid 

Relevant academic research and scientific papers

Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast

The nuclear farnesoid X receptor (FXR) and the enzyme soluble epoxide hydrolase (sEH) are validated molecular targets to treat metabolic disorders such as non-alcoholic steatohepatitis (NASH). Their simultaneous modulation in vivo has demonstrated a triad of anti-NASH effects and thus may generate synergistic efficacy. Here we report dual FXR activators/sEH inhibitors derived from the anti-asthma drug Zafirlukast. Systematic structural optimization of the scaffold has produced favorable dual potency on FXR and sEH while depleting the original cysteinyl leukotriene receptor antagonism of the lead drug. The resulting polypharmacological activity profile holds promise in the treatment of liver-related metabolic diseases.

Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

The dissociation constants (K(B)) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurathane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The K(B) was found to be remarkably toler

Heterocyclic amide derivatives and pharmaceutical use

The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R1, R2, L, X, Y, Z, A1, Q, A2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. STR1